Novel association of DJ-1 with HER3 potentiates HER3 activation and signaling in cancer

HER3/ErbB3 has emerged as a new therapeutic target for cancer. Currently, more than a dozen anti-HER3 antibodies are in clinical trials for treatment of various cancers. However, limited understanding of the complex HER3 signaling in cancer and lack of established biomarkers have made it challenging...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shu, Mukherjee, Seema, Fan, Xuejun, Salameh, Ahmad, Mujoo, Kalpana, Huang, Zhao, Li, Leike, Salazar, Georgina To'a, Zhang, Ningyan, An, Zhiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323190/
https://www.ncbi.nlm.nih.gov/pubmed/27582551
http://dx.doi.org/10.18632/oncotarget.11613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323190/
https://www.ncbi.nlm.nih.gov/pubmed/27582551
http://dx.doi.org/10.18632/oncotarget.11613

Ejemplares similares